ClinicalTrials.gg
CompletedNCT07378579Updated Jan 30, 2026

An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

A Phase 1 interventional study of ESK-001 and Moxifloxacin (400 mg) in Healthy Volunteer, sponsored by Alumis Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Alumis Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.
  • Registered 1 year 5 months after the study started (first participant enrolled Jun 2024, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4) (A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Alumis Inc is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects aged between 18 and 55 years, inclusive. between ≥18.0 and ≤32.0 kg/m2, inclusive, and a minimum body weight of 45 kg.
  • Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
  • In good health, determined by no findings from medical history, 12-lead , vital signs measurements, and clinical laboratory evaluations, and from the physical examination at screening or check-in, as assessed by the investigator (or designee).
  • Serum sodium, potassium, calcium, and magnesium levels are within the normal range at screening and check-in-

Exclusion criteria

Exclusion Criteria:

  • Positive hepatitis panel and/or positive test, surface antigen, or antibodies.
  • or aspartate aminotransferase >1.5 times the , at screening or check-in.
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
  • Surgery within the past three months prior to the first study drug administration determined by the principal investigator to be .
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).
  • History of Gilbert's syndrome or cholecystectomy surgery.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Treatment 1: (Therapeutic dose)

    1 oral dose of ESK-001

    Drug: ESK-001

  • Experimental
    Treatment 2: (Supratherapeutic dose)

    1 oral dose of ESK-001

    Drug: ESK-001

  • Placebo comparator
    Treatment 3: ESK-001-matched placebo

    Drug: Placebo

  • Active comparator
    Treatment 4: (positive control)

    Moxifloxacin 400 mg tablet

    Drug: Moxifloxacin (400 mg)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in placebo-adjusted QTcF (∆∆QTcF)

    Time frame: 24 hours

Secondary outcomes

  1. Change from baseline in ECG parameter ΔHR

    Time frame: 24 hours

  2. Change from baseline in ECG parameter Δ PR interval

    Time frame: 24 hours

  3. Change from baseline in ECG parameter ΔQRS duration

    Time frame: 24 hours

  4. Change from baseline in ECG parameter ΔQTc interval

    Time frame: 24 hours

  5. Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation

    Time frame: Up to 22 Days

  6. Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations

    Time frame: Up to 22 Days

  7. Composite of pharmacokinetic (PK) parameter Vz/F for ESK-001 and metabolites

    Time frame: 24 hours

  8. Composite of pharmacokinetic (PK) parameter Cmax for ESK-001 and metabolites

    Time frame: 24 hours

  9. Composite of pharmacokinetic (PK) parameter tmax for ESK-001 and metabolites

    Time frame: 24 hours

  10. Composite of pharmacokinetic (PK) parameter CL/F for ESK-001 and metabolites

    Time frame: 24 hours

07

Study locations

1 site
  • Fortrea CRU
    Daytona Beach, Florida 32117, United States
08

References and documents

Individual participant data

Plan to share: Undecided — The Sponsor Alumis Inc. is a clinical-stage pharmaceutical company that has not yet adopted an Individual Participant Data (IPD) sharing plan.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Aug 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Jan 30, 2026
StartActual
Jun 21, 2024
Primary completionActual
Aug 31, 2024
CompletionActual
Aug 31, 2024
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07378579
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Jun 21, 2024
Primary completion
Aug 31, 2024
Completion
Aug 31, 2024
Last update
Jan 30, 2026

Study contacts

Jorn Drappa, MD, Ph.D.
study director · Alumis Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Envudeucitinib

Start the discussion